AGC Biologics and RoosterBio Announce Collaboration to Accelerate Manufacturing of Cell and Exosome Therapies

On August 16, 2022, AGC Biologics, a leading global BioContract Development and Manufacturing Organization (CDMO), announced a strategic partnership with RoosterBio, Inc., a leading supplier of human mesenchymal stem/stromal cells (hMSCs), highly engineered media, and bioprocess development services. The partnership creates an end-to-end solution for the development and production of hMSC and exosome therapeutics leveraging RoosterBio’s well-established cell and media products and process development services, coupled with AGC Biologics’ global cell and gene therapy manufacturing capabilities. 

Login Or Register To Read Full Story